Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer

NCT06661122 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06661122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06661122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer
Lead sponsor
Bayer
Phase
Observational
Overall status
Recruiting
Start date
November 18, 2024
Completion date
August 31, 2031
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low-volume metastasis, metastatic hormone-sensitive prostate cancer (mhspc)